Elizabeth Fassbender

Author

Also Known As

ELIZABETH FASSBENDER, Elizabeth Fassbender, Elizabeth S. Fassbender

Publications

204

Citations

H-Index

Concepts

All Affiliations

Elizabeth Fassbender is an author at Novartis (United States) specializing in drug discovery, glaucoma, and medicine.

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	65
2	Pharmacology	2	2	65
3	Drug Discovery	2	2	65
4	Medicinal Chemistry	1	1	36
5	Molecular Pharmacology	1	1	36

Elizabeth Fassbender

Publications

191

Citations

H-Index

Page 1

	Year	Citations
Reliability of the Mouse Model of Choroidal Neovascularization Induced by Laser Photocoagulation Stephen Poor, Yubin Qiu, Elizabeth Fassbender, Investigative Ophthalmology & Visual Science	2014	72
Long-acting protein drugs for the treatment of ocular diseases Joy G. Ghosh, Andrew Nguyen, Chad E. Bigelow, Nature Communications	2017	54
The Discovery of <i>N</i>-(1-Methyl-5-(trifluoromethyl)-1<i>H</i>-pyrazol-3-yl)-5-((6- ((methylamino)methyl)pyrimidin-4-yl)oxy)-1<i>H</i>-indole-1-carboxamide (Acrizanib), a VEGFR-2 Inhibitor Specifically Designed for Topical Ocular Delivery, as a Therapy for Neovascular Age-Related Macular Degeneration Christopher M. Adams, Karen Anderson, Gerald D. Artman, Journal of Medicinal Chemistry Ocular DiseaseChoroidal NeovascularizationPharmacotherapyRetinal TherapiesOcular Pharmacology	2018	36
Discovery of Oral VEGFR-2 Inhibitors with Prolonged Ocular Retention That Are Efficacious in Models of Wet Age-Related Macular Degeneration Erik L. Meredith, Nello Mainolfi, Stephen Poor, Journal of Medicinal Chemistry Translational MedicineOcular DiseaseOphthalmologyProlonged Ocular RetentionWet Amd Patients	2015	29

Page 1